The effect of Ellagic acid supplementation on glycemic index, lipid profile, anthropometric index, dietary intake and serum pentosidine level in patients with type 2 diabetes: a double-blind randomized controlled clinical trial

Abstract

چكيده انگليس ي Results No significant changes were observed in the intake of macronutrients, energy, weight and BMI. A significant decrease in pentosidine serum level was observed after taking EA supplement in the intervention group (P=0.006). Regarding glycemic indices, the average changes observed at the end of the study after adjustment of confounders for insulin measurement (P=0.008) and HbA1c (P=0.031) were significant. The average changes observed for the HOMA-IR variable were not significant at first, but became significant after adjustment of confounding factors (P=0.025). No significant changes were observed in the level of fasting blood sugar (FBS). The results of HDL-C and triglyceride (TG) changes were also not significant. Also, the statistical results related to LDL did not show significant changes after adjustment of confounding factors (P=0.055). However, EA consumption led to a significant decrease in total cholesterol (TC) in T2DM patients (P=0.021). Conclusion The present study provided evidence that receiving EA supplementation can lead to the improvement of some glycemic indices, lipid profile and reduction of pentosidine serum level in patients with T2DM, although it could not have beneficial effects on energy intake, macronutrients and anthropometric measurements in Patients with T2DM. Key words: Type 2 diabetes melius, Glycemic indices, Lipid profile, Pentosidine, Advanced glycation end products